Clinical Trials Logo

Carcinoma, Hepatocellular clinical trials

View clinical trials related to Carcinoma, Hepatocellular.

Filter by:

NCT ID: NCT04994236 Recruiting - Clinical trials for Hepatocellular Carcinoma

Hepatic Artery Infusion Chemotherapy for Unresectable Hepatocelluar Carcinoma Who Failed to Systemic Therapy

Start date: July 1, 2021
Phase: Phase 2
Study type: Interventional

There are limited treatment options for patients with unresectable hepatocellular carcinoma (HCC) who failed to the combination therapy with targeted agents plus anti-PD-1/PD-L1. Hepatic artery infusion chemotherapy (HAIC) had shown potent antitumor effects in single-centered studies when was used as first-line therapy. However, HAIC was not used as second or third-line therapy.

NCT ID: NCT04992143 Recruiting - Clinical trials for BCLC Stage C Hepatocellular Carcinoma

TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC

Start date: August 20, 2021
Phase: Phase 2
Study type: Interventional

According to the BCLC staging system treatment recommendation, systemic treatment is recommended for patients in BCLC stage C, and TACE and systemic treatment are recommended for patients in this stage. Studies have shown that TACE combined with sorafenib therapy has shown effectiveness in the treatment of advanced liver cancer, and PD-1 inhibitors have also shown effectiveness in the treatment of advanced liver cancer. Therefore, in order to improve the survival benefit of BCLC stage C liver cancer patients, this clinical study was designed to evaluate the effectiveness and safety of TACE combined with sorafenib and tislelizumab in the treatment of BCLC stage C liver cancer patients.

NCT ID: NCT04988945 Recruiting - HCC Clinical Trials

TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma

Start date: December 1, 2020
Phase: Phase 2
Study type: Interventional

This study is a prospective phase II, single arm mono-institutional study conducted in Queen Mary Hospital (Hong Kong) assessing the efficacy and safety of the sequential administration of trans-arterial chemo-embolization (TACE) and stereotactic body radiotherapy (SBRT) with immune checkpoint inhibitors in unresectable hepatocellular carcinoma (HCC) patients.

NCT ID: NCT04981665 Recruiting - Clinical trials for Hepatocellular Carcinoma

A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

Start date: November 8, 2021
Phase: Phase 2
Study type: Interventional

This is an open label, multi-center, phaseâ…¡study to evaluate the efficacy and safety of TACE sequential tislelizumab as adjuvant therapy in hepatocellular carcinoma (HCC) patients who are at high risk of recurrence after curative resection.

NCT ID: NCT04976634 Recruiting - Clinical trials for Colorectal Neoplasms

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

Start date: August 18, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumors including hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), endometrial cancer (EC),and esophageal squamous cell carcinoma (ESCC). There is no formal hypothesis testing in this study.

NCT ID: NCT04974281 Recruiting - Clinical trials for Hepatocellular Carcinoma

PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC

Start date: January 1, 2021
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to assess the difference of safety and efficacy about PD-1 Antibody and Lenvatinib Plus transcatheter arterial chemoembolization (TACE) on downstaging hepatocellular carcinoma with BCLC B/C.

NCT ID: NCT04973098 Recruiting - Clinical trials for Advanced Hepatocellular Carcinoma

Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular Carcinoma

Start date: August 5, 2021
Phase: Phase 1
Study type: Interventional

A Phase I Clinical Study of CT0181 cells in Patients with Advanced Hepatocellular Carcinoma

NCT ID: NCT04967495 Recruiting - Clinical trials for Hepatocellular Carcinoma Non-resectable

TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT

Start date: July 9, 2021
Phase: N/A
Study type: Interventional

This study is conducted to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with lenvatinib and iodion-125 seeds brachytherapy (TACE-Len-I) compared with TACE combined with lenvatinib (TACE-Len) for hepatocellular carcinoma (HCC) with portal vein branch tumor thrombus (branch PVTT).

NCT ID: NCT04967482 Recruiting - Clinical trials for Hepatocellular Carcinoma Non-resectable

DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC

Start date: July 9, 2021
Phase: N/A
Study type: Interventional

This study is conducted to evaluate the efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) compared with conventional transarterial chemoembolization (cTACE) as the conversion therapy for unresectable large hepatocellular carcinoma (HCC).

NCT ID: NCT04965454 Recruiting - Clinical trials for Hepatocellular Carcinoma Non-resectable

Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma

ExTRACT-HCC
Start date: March 28, 2022
Phase: Phase 2
Study type: Interventional

This prospective clinical trial will evaluate PET/CT and genomic liquid biopsy based biomarkers as predictors of clinical therapeutic response to immune-checkpoint inhibitor (ICI) therapy for patients with inoperable hepatocellular carcinoma (HCC). The primary objective of this diagnostic trial is to assess the accuracy of pre-treatment fluorine-18 (18F-) fluorocholine (FCH) PET/CT for predicting a lack of objective response (LOR) after 16 weeks of ICI therapy.